 P2Y12 antagonists that inhibit platelet activation and corticosteroids and cysteinyl leukotriene receptor 1 antagonists that suppress allergic and/or inflammatory reactions) are effective treatments for many putatively TP-dependent diseases.These drugs are likely to be cheaper and may prove to have more severe side effects that TP-targeting drugs.These considerations may help to explain why relatively few studies have examinted the clinical usefulness of TP-targeting drugs.